Compare LITB & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LITB | MNOV |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.1M | 67.9M |
| IPO Year | 2013 | 2004 |
| Metric | LITB | MNOV |
|---|---|---|
| Price | $3.23 | $1.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 3.8K | ★ 37.0K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | $14.50 | N/A |
| Revenue Next Year | $11.59 | $180.00 |
| P/E Ratio | $10.96 | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $1.15 | $1.17 |
| 52 Week High | $4.17 | $1.96 |
| Indicator | LITB | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 47.15 | 47.47 |
| Support Level | $2.81 | $1.30 |
| Resistance Level | $3.36 | $1.46 |
| Average True Range (ATR) | 0.22 | 0.04 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 35.00 | 33.33 |
LightInTheBox Holding Co Ltd is a e-commerce company, providing a diverse range of affordable lifestyle products directly to consumers. Its brands include Ador, a women's fashion brand targeting women aged 35-55; the second is a golf apparel brand focusing on female golfers aged 35 and above; the third is a women's light party dress brand for the age group of 30 and above. It offers customers products through websites and mobile applications. The company operates and reviews its performance in two segments: Product sales which consisted of online retailing of consumer products and sales to third-party sellers, and Services which consisted of the provision of logistic services to companies and individual customers.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.